Diamond Equity Research | IMU: Strategic Sale of North Carolina Facility and Clinical Trial Expansions Advancing

Bell Potter | Imugene Core Assets Progressing Nicely

Roth Capital Partners | IMU: Sells CGMP Facility That Manufactures Azer-cel, MAST Trial Making Progress

Diamond Equity Research | Imugene Financial Report Highlights Continuous Pipeline Progression and Other Strategic Advances

Roth Capital Partners | Clinical Progress With onCARlytics And VAXINIA In Solid Tumors

Diamond Equity Research | VAXINIA’s Releases Early Positive Data, PD1-Vaxx and Azer-cel Advancing Through Clinical Pipeline

ROTH Capital Partners | MAST Trial Evaluating VAXINIA Oncolytic Viral Yields More Positive Data

BIO SHARES | Investor Interest Starts Return to Biotech Sector

BIO SHARES | First Results for Imugene's Oncolytic Virus CF33

Bell Potter: No Time To Waste – Azer-cel Back In The Clinic

Valuation $0.15

ROTH•MKM IMU: Positive Initial VAXINIA MAST Trial Data, Expanding Bile Duct Tumor Cohort

12-month target: AUD0.46

DIAMOND EQUITY RESEARCH | Immuno-oncology Innovations Highlighted at ESMO, Financial Position Strengthened, and Clinical Pipeline Advancing

Valuation: A$0.49

ROTH•MKM IMU: Initiates Dosing In First Cancer Trial Combining onCARlytics With Blincyto

12-month target: AUD0.46

ROTH•MKM | IMU: 3 ESMO Posters Highlight HER-Vaxx & Oncolytic Virus CF33-hNIS-antiPD-L1

12-month target: AUD0.51

ROTH•MKM | IMU: Licenses Clinical Stage Allogeneic CD19 CAR T For Liquid Tumors

12-month target: AUD0.71

DIAMOND EQUITY RESEARCH | Imugene Secures Promising Allogeneic CAR-T Cell Therapy Asset, Expanding Pipeline and Addressable Market

Valuation: A$0.54

ROTH•MKM | U.S. Oncolytic Virus Patent Allowed, Enrolling 4th CHECKvacc Dose Cohort

12-month target: AUD0.71

ROTH•MKM | Doses First Combination NSCLC Patient in PD1-Vaxx + Tecentriq Phase 1/1b

12-month target: AUD0.71

DIAMOND EQUITY RESEARCH | IND Clearance Enables OnCARlytics to enter Human Clinical Trials

Valuation: A$0.46

31 May 2023

BELL POTTER | First In Human Trial For onCARlytics

19 May 2023

BIO SHARES | Imugene: Nine Clinical Programs to Advance in 2023

6 April 2023

DIAMOND Equity Research | H1 FY2023 Financial Result Update and Progress with Clinical Trials

Valuation: 46c AUD

6 March 2023

ROTH Capital Partners | Updating Financial Model Following Release of FY1H23 Financials

12 month price target: 71c AUD

23 February 2023

DIAMOND Equity Research | Initial Clinical Trial Data Encouraging with Strong Financial Position

Valuation: 46c AUD

30 January 2023

ROTH Capital Partners | IMU: Presents First Two CHECKVacc DoseCohorts at SABCS, Showing Clean Safety

12 month price target: 71c AUD

11 December 2022

ROTH Capital Partners | Favorable Phase 2 HER-Vaxx DoR Data Presented at the ESMO Asia Congress

12 month price target: 71c AUD

5 December 2022

DIAMOND EQUITY RESEARCH | OnCARlytics Pre-Clinical Highlights and Continued Progress on Multiple Fronts

Valuation: 46c AUD

23 November 2022

DIAMOND EQUITY RESEARCH | Therapeutic Cancer Vaccines and Oncolytic Virus Powered Immunotherapies Targeting Solid Tumors

Price Target 48c USD

29 September 2022

ROTH Capital Partners | Recent Clinical Highlights from Last Week Underscore Continued Progress

Price Target 71c AUD

14 August 2022

ROTH Capital Partners | Highly Positive Final Phase 2 HER-VaxxSurvival Data Justifies More Trials

Price Target 71c AUD.

27 June 2022

Noble Life Science Partners | Progress Continues With New Trial and ASCO Abstracts

Price target 50c USD.

1 June 2022

ROTH Capital Partners | First Phase 1 Advanced Solid Tumor Patient Dosed with CF33-hNIS VAXINIA

12-month share price target 71c AUD.

18 May 2022

ROTH Capital Partners | CHECKvacc Enters Second Dose Cohort, Cleared to Start U.S. VAXINIA Phase 1.

12-month share price target 71c AUD.

24 March 2022

ROTH Capital Partners | IMU.AX: Supply Deal with Merck KGaA & PFE for BAVENCIO/Chemo/HER-Vaxx Ph2 Trial. We raise our PT to AUD0.71 from AUD0.62.

16 November 2021

ROTH Capital Partners | IMU.AX: Solid Tumor Partnership with Eureka Therapeutics, Raising PT to AUD0.62

1 November 2021

Screen Shot 2021-09-02 at 10.00.52 am.png

BELL POTTER | HER-vaxx Program To Expand. Target 52 cents.

2 September 2021

BioShares | Bioshares 900 Special Edition: Top 10 Events in Australian Biotech in the Last 100 Editions

#7. Imugene - The Most Recent Billion Dollar Biotech Raises $90 Million

25 August 2021

Screen Shot 2021-08-13 at 12.51.36 pm.png

BioShares | Imugene Secures $90 Million Transformational Capital Raise

11 August 2021

Screen Shot 2021-07-09 at 9.24.38 am.png

ROTH Capital Partners | IMU.AX: IND Cleared for U.S. Phase 1 Trial Initiation with CHECKvacc in TNBC

6 July 2021

Screen Shot 2021-05-19 at 9.48.05 am.png

ROTH Capital Partners | IMU: Licenses Oncolytic Virus That Enables CAR T Therapy to Target Solid Tumors

18 May 2021

Screen Shot 2021-04-08 at 8.56.22 am.png

ROTH Capital Partners | IMU: Efficacy & No Safety Issues in Second PD1-Vaxx Dose Cohort; Third Starting

7 April 2021

Screen Shot 2021-03-09 at 9.44.32 am.png

ROTH Capital Partners | IMU.AX 1H21 Results: Solid HER-Vaxx & PD1-

Vaxx Clinical Progress Despite COVID

8 March 2021


Screen Shot 2020-12-03 at 11.17.52 am.png

BELL POTTER | Imugene (IMU) HER-2 VAXX shows 5.4m OS benefit

Investment View: Retain Buy (Speculative)

3 December 2020

Screen Shot 2020-12-03 at 9.33.55 am.png

ROTH Capital Partners | Imugene Limited IMU.AX - $0.13 - ASX | BUY

IMU.AX: Initiates Phase 1 Dosing With PD1-Vaxx in NSCLC

1 December 2020

Screen Shot 2020-12-21 at 12.20.43 pm.png

Pharma and Biotech Newsletter | IMU was the second best performing stock in the index in November, with the share price increasing 114.3%.

November 2020


Screen Shot 2020-11-24 at 4.58.55 pm.png

ROTH Capital Partners | Imugene Limited IMU.AX - $0.13 - ASX | BUY

IMU.AX: Interim Phase 2 Data Show HERVaxx OS Benefit, Raising PT to $0.20

23 November 2020

Screen Shot 2020-11-12 at 11.07.01 am.png

ROTH Capital Partners | Imugene Limited IMU.AX - AUD0.06 - ASX | Buy IMU.AX

1QFY21 Cash Flows, PD1-Vaxx IND Cleared in U.S., U.S. Patent Granted

11 November 2020

Screen Shot 2020-10-01 at 5.23.22 pm.png

ROTH Capital Partners | Imugene Limited IMU.AX - AUD0.05 - ASX | Buy IMU.AX

Engineered Oncolytic Viruses and B Cell Immunotherapies to Fight Cancer

01 October 2020

Screen Shot 2020-05-13 at 8.00.48 am.png

Bell Potter | Imugene (IMU) Deep Pipeline, Max Potential

The Future Of Cancer Therapy

13 May 2020

Screen Shot 2020-05-12 at 8.23.02 am.png

BioShares | Imugene Well Positioned With $34 Million in Cash

Page 5.

May 11, 2020

Screen Shot 2019-11-12 at 8.31.45 am.png

BioShares | Imugene Expanding Oncology Pipeline

November 11, 2019


Screen Shot 2019-07-24 at 11.23.50 am.png

BioShares | Imugene To Expand Portfolio With License of Oncolytic Virotherapy

July 22, 2019

Edison Research Note | In-Licensing deal for CF33 oncolytic virus

July 15, 2019

Screen Shot 2019-07-14 at 4.03.50 pm.png

Australian Research Independent Investment Research | Imugene Limited (ASX: IMU) Initiating Coverage

July 15, 2019

Screen Shot 2019-07-15 at 2.18.23 pm.png

Edison Research Note | HER-Vaxx Phase II underway

April 15, 2019

Screen Shot 2018-10-29 at 12.30.17 pm.png

BioShares | Imugene prepares for Phase IIa Study

September 14, 2018

Screen Shot 2019-07-15 at 2.20.07 pm.png

Edison Research Note | Checkpoint inhibitor vaccine programme accelerated

August 16, 2018

Screen Shot 2018-10-29 at 12.51.56 pm.png

BioWorld | Aussie biotech Imugene leads pack in HER2-targeting B-cell immunotherapies

January 22, 2018

Screen Shot 2018-10-29 at 12.56.22 pm.png

BioShares | Imugene Set To Commence Phase Ib/II Gastric Cancer Trial

June 3, 2016

Screen Shot 2018-10-29 at 12.59.34 pm.png

Red Chip Research Report | Anti-tumour vaccine trial to start mid-2016

April 18, 2016

Screen Shot 2018-10-29 at 1.08.47 pm.png

Edison Research Note | Anti-tumour vaccine trial to start mid-2016

February 19, 2016

Screen Shot 2018-10-29 at 1.12.33 pm.png

BioShares | Imugene Adopts a Portfolio Model to Become a B Cell Vaccines Play

January 22, 2016